id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-296147-yfcp0xf2	Mairesse, Antoine	High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies	2020-08-25		.txt	text/plain	3217	226	56	This study aims at assessing the analytical and clinical performances of the iFlash® anti-SARS-CoV-2 chemiluminescence assay for the detection of both IgM and IgG antibodies. The determination of anti-SARS-CoV-2 IgG antibodies from 28 days since symptom onset was associated with high sensitivity, especially using optimized cut-offs (i.e. 100%). The aim of this study was to evaluate the analytical and clinical performances of the iFlash ® SARS-CoV-2 antibodies (IgM and IgG) chemiluminescence assay (CLIA). Clinical sensitivity for SARS-Cov-2 serological test depending on the onset of COVID-19 symptoms was carried out with the manufacturer's cut-off (>10 AU/mL for both IgM and IgG) and with ROC curve adapted cut-offs (2.81 AU/mL for IgM; 4.86 AU/mL for IgG). The aims of the present study were to evaluate the analytical and clinical performances of the iFlash ® anti-SARS-CoV-2 CLIA assay for IgM and IgG antibodies with a large cohort of COVID-19 patients, to provide an external validation of this test and to evaluate the antibody kinetics since symptom onset.	./cache/cord-296147-yfcp0xf2.txt	./txt/cord-296147-yfcp0xf2.txt